426 related articles for article (PubMed ID: 28448462)
21. Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Kuca K
Curr Cancer Drug Targets; 2016; 16(3):200-8. PubMed ID: 26882028
[TBL] [Abstract][Full Text] [Related]
22. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
23. Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells.
Mordasini V; Ueda S; Aslandogmus R; Berger C; Gysin C; Hühn D; Sartori AA; Bernasconi M; Nadal D
Oncotarget; 2017 Jan; 8(4):6461-6474. PubMed ID: 28031537
[TBL] [Abstract][Full Text] [Related]
24. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
[TBL] [Abstract][Full Text] [Related]
25. Novel insights into Chk1 regulation by phosphorylation.
Goto H; Kasahara K; Inagaki M
Cell Struct Funct; 2015; 40(1):43-50. PubMed ID: 25748360
[TBL] [Abstract][Full Text] [Related]
26. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
27. Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.
Soares DG; Battistella A; Rocca CJ; Matuo R; Henriques JA; Larsen AK; Escargueil AE
Biochem J; 2011 Jul; 437(1):63-73. PubMed ID: 21470188
[TBL] [Abstract][Full Text] [Related]
28. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy.
Ahmed S; Alam W; Aschner M; Alsharif KF; Albrakati A; Saso L; Khan H
Biomed Pharmacother; 2022 Nov; 155():113797. PubMed ID: 36271573
[TBL] [Abstract][Full Text] [Related]
29. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
30. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.
Weng MT; Tung TH; Lee JH; Wei SC; Lin HL; Huang YJ; Wong JM; Luo J; Sheu JC
Sci Rep; 2015 Apr; 5():9357. PubMed ID: 25880358
[TBL] [Abstract][Full Text] [Related]
31. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.
Wang H; Wang X; Zhou XY; Chen DJ; Li GC; Iliakis G; Wang Y
Cancer Res; 2002 May; 62(9):2483-7. PubMed ID: 11980637
[TBL] [Abstract][Full Text] [Related]
32. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
35. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
36. REV1 is important for the ATR-Chk1 DNA damage response pathway in Xenopus egg extracts.
DeStephanis D; McLeod M; Yan S
Biochem Biophys Res Commun; 2015 May; 460(3):609-15. PubMed ID: 25800873
[TBL] [Abstract][Full Text] [Related]
37. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
38. Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.
Biswas H; Makinwa Y; Zou Y
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511442
[TBL] [Abstract][Full Text] [Related]
39. 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.
Yang C; Fan P; Zhu S; Yang H; Jin X; Wu H
Oncol Lett; 2018 Jun; 15(6):8878-8884. PubMed ID: 29805624
[TBL] [Abstract][Full Text] [Related]
40. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
